MARATTO

article · Egyptian Journal of Chemistry

The Expression Profile of MicroRNA LET-7a-5p in Children with Idiopathic Thrombocytopenic Purpura

Abstract

Background: Pediatric immune thrombocytopenia (ITP) is an autoimmune condition whose cause is unclear and appears to include a number of different factors. Methods: In this investigation, quantitative real-time PCR was used to examine the expression profiles of the miRNA Let-7a-5p in blood samples from children with ITP and healthy controls (HCs). It was also examined whether miRNA Let-7a-5p was associated with ITP clinical characteristic parameters and whether it's potential usage as non-invasive circulating biomarkers for ITP diagnosis. The area under the curve was analysed after the receiver operating characteristic curve was generated.Results: When compared to HCs, ITP patients' levels of the miRNA Let-7a-5p were considerably significant higher (P < 0.0001). Furthermore, there was a strong positive correlation between the expression level of the Let-7a-5p biomarker and the patients' levels of the antiplatelet antibody glycoproteins GPIIIa, GPIIb, and GP1b/IX (r = 0.637, 0.669 and 0.486).For miRNA Let-7a-5p, the biomarker demonstrated excellent specificity (96.8) and sensitivity (100%) at cutoff values of > 18.5. Serum miRNA Let-7a-5p may be used as a possible biomarker to distinguish between HCs and children with ITP.

Research topics

  • Platelet Disorders and Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Renal Diseases and Glomerulopathies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ejchem.2024.249718.8897

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.